G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency

International Journal of Cancer

Volumn 132, Issue 2, 2013, Pages 315-326

  Im, Jae Hong ^a   Tapmeier, Thomas ^a   Balathasan, Lukxmi ^a   Gal, Annamaria ^a   Yameen, Sabira ^a   Hill, Sally ^a   Smart, Sean ^a   Noterdaeme, Olivier ^b   Kelly, Matthew ^b   Brady, Michael ^b   Fu, Weili ^c   Kruse, Karoline ^d   Bernhard, Eric J ^a   Augustin, Hellmut G ^d   Muschel, Ruth J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

angiogenesis; angiopoietin 2; G CSF; liver; lung; metastasis; neutrophils; vascular leakage

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; CD11B ANTIGEN; CD31 ANTIGEN; CXCL1 CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD VESSEL PARAMETERS; CANCER PATIENT; COLONY FORMATION; CONTROLLED STUDY; GENOTYPE; HOST; LIVER METASTASIS; METASTASIS; MOUSE; MOUSE STRAIN; NEUTROPHIL; NONHUMAN; PERICYTE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEPLETION; TUMOR GROWTH; TUMOR SEEDING; TUMOR VASCULARIZATION; VASCULAR DENSITY; WILD TYPE;

ADENOCARCINOMA; ANGIOPOIETIN-2; ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD31; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GREEN FLUORESCENT PROTEINS; LIVER; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHILS; RECEPTOR PROTEIN-TYROSINE KINASES; STATISTICS, NONPARAMETRIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84869506980     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27677     Document Type: Article

References (50)

1. Ferrara N, Kerbel RS,. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
2. Carmeliet P, De Smet F, Loges S, et al. Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol 2009; 6: 315-26.
3. Chen HX, Cleck JN,. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.
4. Carmeliet P, Jain RK,. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
5. Fiedler U, Augustin HG,. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-8.
6. Yuan HT, Khankin EV, Karumanchi SA, et al. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009; 29: 2011-22.
7. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
8. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-9.
9. Cao Y, Sonveaux P, Liu S, et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007; 67: 3835-44.
10. Feng Y, vom Hagen F, Pfister F, et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost 2007; 97: 99-108.
11. Yu Q, Stamenkovic I,. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 2001; 158: 563-70.
12. Helfrich I, Edler L, Sucker A, et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009; 15: 1384-92.
13. Sarraf-Yazdi S, Mi J, Moeller BJ, et al. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J Surg Res 2008; 146: 16-23.
14. Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70: 2213-23.
15. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6: 507-16.
16. Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19: 512-26.
17. Holopainen T, Saharinen P, D'Amico G, et al. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 2012; 104: 461-75.
18. Scharpfenecker M, Fiedler U, Reiss Y, et al. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005; 118: 771-80.
19. Gorden DL, Fingleton B, Crawford HC, et al. Resident stromal cell-derived MMP-9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer 2007; 121: 495-500.
20. Im JH, Fu W, Wang H, et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 2004; 64: 8613-19.
21. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002; 3: 411-23.
22. Chekenya M, Enger PO, Thorsen F, et al. The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol 2002; 28: 367-80.
23. Stallcup WB,. The NG2 proteoglycan: past insights and future prospects. J Neurocytol 2002; 31: 423-35.
24. Vestweber D, Winderlich M, Cagna G, et al. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol 2009; 19: 8-15.
25. De Palma M, Murdoch C, Venneri MA, et al. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007; 28: 519-24.
26. Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8: 618-31.
27. Welford AF, Biziato D, Coffelt SB, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011; 121: 1969-73.
28. Kimura YN, Watari K, Fotovati A, et al. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 2007; 98: 2009-18.
29. Auguste P, Fallavollita L, Wang N, et al. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am J Pathol 2007; 170: 1781-92.
30. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475: 222-5.
31. Tazzyman S, Lewis CE, Murdoch C,. Neutrophils: key mediators of tumour angiogenesis. Int J Exp Pathol 2009; 90: 222-31.
32. Cuenca RE, Azizkhan RG, Haskill S,. Characterization of GRO alpha, beta and gamma expression in human colonic tumours: potential significance of cytokine involvement. Surg Oncol 1992; 1: 323-9.
33. Kohler A, De Filippo K, Hasenberg M, et al. G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood 2011; 117: 4349-57.
34. Bekes EM, Schweighofer B, Kupriyanova TA, et al. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation. Am J Pathol 2011; 179: 1455-70.
35. Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 2002; 16: 267-9.
36. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009; 106: 6742-7.
37. Kowanetz M, Wu X, Lee J, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci USA 2010; 107: 21248-55.
38. Yoshioka T, Takahashi M, Shiba Y, et al. Granulocyte colony-stimulating factor (G-CSF) accelerates reendothelialization and reduces neointimal formation after vascular injury in mice. Cardiovasc Res 2006; 70: 61-9.
39. Renard N, Duvert V, Banchereau J, et al. Interleukin-13 inhibits the proliferation of normal and leukemic human B-cell precursors. Blood 1994; 84: 2253-60.
40. Kawakami K, Kawakami M, Snoy PJ, et al. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 2001; 194: 1743-54.
41. Wynn TA,. IL-13 effector functions. Annu Rev Immunol 2003; 21: 425-56.
42. Bessard A, Sole V, Bouchaud G, et al. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8: 2736-45.
43. Kobayashi H, Dubois S, Sato N, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005; 105: 721-7.
44. Deak E, Gottig S, Ruster B, et al. Bone marrow derived cells in the tumour microenvironment contain cells with primitive haematopoietic phenotype. J Cell Mol Med 2010; 14: 1946-52.
45. Pucci F, Venneri MA, Biziato D, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114: 901-14.
46. Coffelt SB, Chen YY, Muthana M, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011; 186: 4183-90.
47. Goede V, Coutelle O, Neuneier J, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 2010; 103: 1407-14.
48. Ogawa M, Yamamoto H, Nagano H, et al. Hepatic expression of ANG2 RNA in metastatic colorectal cancer. Hepatology 2004; 39: 528-39.
49. Hu J, Bianchi F, Ferguson M, et al. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene 2005; 24: 1212-19.
50. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27: 3557-65.